Key result
Pregnancy in women with prosthetic heart valves on anticoagulation had higher thromboembolic, hemorrhagic, and fetal complications than controls.
Why the study?
Does having a prosthetic heart valve managed with anticoagulant therapy increase maternal and fetal complications in pregnant women compared to healthy controls?
Observational (n=198)
Does having a prosthetic heart valve managed with anticoagulant therapy increase maternal and fetal complications in pregnant women compared to healthy controls?
Answers are grounded in this paper and cite their sources.
Pregnancy in women with prosthetic heart valves on sequential heparin/warfarin therapy carries significantly higher risks of thromboembolic, hemorrhagic, and fetal complications compared to healthy pregnancies.
Objectives To investigate maternal and fetal outcomes of pregnancy in women with prosthetic heart valves on anticoagulant therapy. Study design A prospective clinical trial. Patients and methods The study was conducted on 66 pregnant women with prosthetic heart valves on anticoagulant therapy (cases) and 132 normotensive, nondiabetic pregnant women without heart problems (control group). All cases were on unfractionated heparin during the first trimester, on warfarin during the second trimester, and then on heparin again from 36 weeks. Results We found that 4.5% of our cases had thromboembolic complications, 9.1% had hemorrhagic complications, and fetal losses were about 15.2%. These complications were significantly higher in the cases compared with the control group (P=0.036, 0.018, and 0.014, respectively). Thromboembolic complications were higher in women taking low-dose (≤5 mg) warfarin (11.5%), and neonatal deaths were higher in the high-dose (>5 mg) group (5.0%). The position of the prosthetic valve (mitral or aortic), the duration since valve replacement, the ejection fraction, and the international normalized ratio value had no impact on the outcome of pregnancy. Conclusion Pregnancy in patients with prosthetic heart valves is still associated with increased incidence of maternal and fetal complications. Therefore, patients with prosthetic valves need to be followed throughout pregnancy by both the obstetrician and the cardiologist; and should be fully informed of the potential risks and benefits of various therapeutic regimens.
No takes yet. Share an insight, caveat, or question.
El-Raouf et al. (2013) conducted an observational in Pregnancy with prosthetic heart valves (n=198). Prosthetic heart valves on anticoagulant therapy vs. Normotensive, nondiabetic pregnant women without heart problems was evaluated on Thromboembolic complications (p=0.036). Pregnancy in women with prosthetic heart valves on anticoagulation had higher thromboembolic, hemorrhagic, and fetal complications than controls.
Synapse has enriched 10 related papers. Consider them for comparative context: